FluGen Studies Show Progress Toward Universal Flu Vaccine

Source: Milwaukee Journal Sentinel (WI)

By: Gallagher, Kathleen


A vaccine that FluGen in Madison, Wis., has in development could be taken every three to five years and protect against a wide range of flu viruses. The vaccine could even protect against viruses it was not designed to prevent. The vaccine and vaccine delivery product company presented data from studies on animals at the World Health Organization meeting in Hong Kong in January. Clinical trials for the cell-based vaccine, called Redee Flu, could begin in 2014 and be ready for the market by 2019. “We believe the data so far shows we have all the qualities of a universal vaccine and could be first one with a universal three- to five-year vaccine,” said Paul Radspinner, FluGen’s president and chief executive officer.

Copyright © 2014 Information, Inc.